TruthArchive.ai - Related Video Feed

Dr. Hotez explains that while vaccines are often described as miraculous, the development was not a four-month process but a seventeen-year effort dating back to the post-SARS period. After SARS emerged in 2003, researchers identified the spike protein as the virus’s soft underbelly and began experimental vaccine development. When the COVID-19 sequence was released in January, the coronavirus community quickly concluded that a vaccine could be made, and attention turned to which technology would be fastest and most enduring. All vaccines discussed (AstraZeneca, Pfizer, Moderna, J&J, and the one being scaled in India) target the spike protein. He emphasizes that this was a deliberate long-term program, not a rushed push. Nicole notes the broader context of vaccine safety, particularly on a day when a vaccine-skeptical witness testified before the Senate Homeland Security Committee. Dr. Hotez clarifies that the virus behind the current pandemic comes from a family of coronaviruses scientists have studied for a long time, and that once specifics emerged, researchers could finalize the vaccine approach. He reiterates the importance of reassurance about safety in light of public skepticism. Dr. Hotez highlights the role of the NIH and the National Institute of Allergy and Infectious Diseases, led by Tony Fauci, and Francis Collins at NIH, in launching a major coronavirus program beginning in 2003. This funding enabled the development of some of the first prototype vaccines, illustrating a deliberate US government and NIH investment to advance vaccine research. He notes the ongoing need to assess rollout and production robustness, as this technology is brand new, and additional vaccines will be necessary to vaccinate populations. Looking ahead, the conversation acknowledges that the United States will require four or five different vaccines to achieve broad vaccination coverage, rather than relying solely on the two mRNA vaccines. The UK has begun vaccinations, marking an initial step, with plans to scale in the United States in the coming days. The discussion underscores a long road ahead to ensure scalable production, distribution, and multiple vaccine options to meet demand.

We isolated coronaviruses from animals in the past to understand their threat to other species by culturing them on different cell types. This process, known as gain of function, involves enriching mutants that can infect new species. The speaker emphasizes that mass vaccination in humans is a significant gain of function experiment, leading to virus evolution. This real-world experiment involves constant virus changes due to human-to-human transmission under vaccine pressure.

mRNA vaccines code for a small part of viral proteins, usually a single antigen. A single mutation can make the vaccine ineffective. This drives antigenic shift, where the vaccine encourages new mutations, prolonging pandemics as the virus mutates to escape the vaccine's protection. Millions caught the Omicron variant despite vaccination because a single mutation can render mRNA vaccines ineffective. The same risk applies to the flu.

Now that we're coming out of the pandemic, the issue of variants will mainly be discussed by specialists. They will talk about the impact of these variants in conferences. Currently, the planned vaccination covers all variants. And does vaccination limit the emergence of new variants? Absolutely, by reducing the number of affected individuals. It decreases the portion of the population where the virus can multiply and mutate, thus leading to new variants. So, vaccination is absolutely essential to control the situation.

The FDA is considering simplifying COVID vaccinations to one shot annually, similar to the flu shot. Researchers are also developing an mRNA flu vaccine, leveraging technology used in COVID vaccines. Traditional vaccines introduce weakened germs, while mRNA vaccines teach cells to produce proteins that trigger immune responses. This new flu vaccine could be adjusted more easily for different strains during flu season. Although the mRNA flu vaccine may not be superior to traditional ones, it offers an alternative for those who cannot tolerate existing vaccines. Current studies on mRNA vaccines are also exploring options for Lyme disease, rabies, HIV, and Zika, with results for the flu vaccine expected by March.

Over the past few weeks, BARDA reviewed 22 mRNA vaccine development investments and began canceling them. Here's the problem: mRNA only codes for a small part of the viral proteins, usually a single antigen. One mutation and the vaccine becomes ineffective. That's because a single mutation can make mRNA vaccines ineffective. After reviewing the science and consulting top experts at NIH and FDA, HHS has determined that mRNA technology poses more risk than benefits for these respiratory viruses. To replace the troubled mRNA programs, we're prioritizing the development of the safer, broader vaccine strategies like whole virus vaccines and novel platforms that don't collapse when viruses mutate. Let me be absolutely clear: HHS supports safe, effective vaccines for every American who wants them.

Researchers at McMaster University are developing a needle-free, inhaled COVID-19 vaccine called AeroVax, a mucosal vaccine administered directly into the lungs to generate a targeted immune response. Phase one is complete, and phase two is recruiting participants. The vaccine is viral vector-based, using the adenovirus with spliced genes from the COVID virus, but contains no live COVID. It includes three COVID virus antigens, intended to produce a more robust and broader immune response, including t-cells, b-cells, and an innate immune response. The innate immune system may offer protection against other viruses and variants. Administered via a specialized inhaler, the vaccine uses particles tiny enough to reach deep into the lung. The dosage is about 100 times less than injectable vaccines, reducing manufacturing costs. Inhalation is believed to be more effective and addresses needle hesitancy. Researchers hope to bring the inhaled vaccine to market in the next five years.

The speakers discuss the expected mutation of the virus and the impact of vaccination. They acknowledge that as people become immunized, the virus will try to find ways to evade the vaccine. The more people are vaccinated, the more pressure is put on the virus to mutate. Some virologists warn that vaccinating the entire world with narrow immunity could lead to the emergence of superbugs. They urge for the use of the right vaccine in the right place and caution against mass vaccination during a pandemic. They argue that current interventions and mass vaccination may be causing more harm than good, driving the emergence of more infectious and potentially lethal variants.

The goal is to stabilize the healthcare system and prevent crisis situations during pandemics. Vaccinating as many people as possible is crucial, and in the future, influenza vaccination could become routine for everyone. Eventually, a universal vaccine may be developed, reducing the need for frequent vaccinations. This would protect people from both seasonal and pandemic flu. This approach benefits both the public and vaccine companies, as they can predict that the majority of the American population will be vaccinated every year, eliminating uncertainty.

We are working on developing new vaccines like TB and HIV using mRNA technology to make them high quality and low cost. Current COVID vaccines are not perfect, so we are working on new versions with longer-lasting protection for diseases like measles and tuberculosis. The mRNA technology also shows promise for cancer vaccines and rapid adaptation to future pandemics. We are even exploring using this technology for animal vaccines.

Today, we began a phase one trial on a nanoparticle that uses multiple different hemagglutinins, which are showing great promise. Our goal is to improve flu vaccines by creating a broadly protective influenza vaccine using a computationally designed nanoparticle platform. These nanoparticles display the virus protein repetitively, which triggers a strong immune response. We also discovered that our nanoparticle platform can display multiple hemagglutinins on the same particle, resulting in broader immune responses. In addition to protecting against current seasonal influenza strains, our vaccine also showed protection against H5N1 bird flu and H7N9. This project was done in collaboration with researchers at the NIH's vaccine research center. This is what our nanoparticle mosaic approach towards a universal flu vaccine looks like.

Yale University scientists have made progress in developing a discreet method of vaccine delivery. They successfully vaccinated mice using two doses of a nasal vaccine containing mRNA COVID vaccine nanoparticles, without any injections. The researchers claim that this new delivery method is both safe and effective. While fact checkers may argue that the government has no plans to vaccinate people through the air, two important points should be noted.

The most urgent invention is a COVID-19 vaccine, which teaches the immune system about the pathogen, specifically the coronavirus and its spike protein. The spike protein grabs cells and causes them to make billions of copies of the virus. Vaccines expose the body to something that looks like the virus, prompting the body to create antibodies to kill it. Vaccine creation usually involves injecting part of the virus's shape. This can be the whole virus, attenuated, or killed. Often, just a piece of the virus or the spike is used, eliminating the risk of causing disease. A promising new method is the RNA vaccine, which uses instructions to make the spike's shape. The Gates Foundation and partners are exploring these efforts. Creating a new vaccine typically takes at least 5 years, but there is optimism that a vaccine will be available in the next 18 months, produced in volume, and accessible worldwide, which will end the pandemic.

NIH is pursuing a universal vaccine designed to cover the entire range of viruses, aiming to mimic natural immunity. The developers claim it would be effective against any mutation and would not drive the virus to mutate. They expect the approach could work not only for coronaviruses but also for flu, offering broad protection. They describe the vaccine as safer and more effective than current options. The dialogue centers on ongoing questions as the project advances, emphasizing a shift toward a single, universal solution that could, if successful, provide cross-viral protection and reduce the need for virus-specific vaccines. The statements focus on safety, efficacy, and cross-coverage across coronaviruses and influenza.

Ohio State University scientists published research exploring the incorporation of a coronavirus antigen into the measles, mumps, rubella (MMR) vaccine to produce COVID-19 immunity in children. The study used a modified live attenuated mumps virus for delivery and a more stable prefusion version of the SARS-CoV-2 spike protein (6P). Experiments showed the 6P antigen induced significantly more neutralizing antibodies in mice and hamsters than the 2P version used in existing mRNA and adenovirus-based COVID-19 vaccines. The modified mumps vaccine generated high levels of the 6P protein, triggering a strong immune response and protection from lung damage. The 6P vaccine induced neutralizing antibodies and T-cell activity against several variants of concern. Researchers also explored intranasal delivery, which induced IgA antibodies on mucosal surfaces of the airways, potentially offering superior protection compared to injected vaccines. The findings suggest existing immunity to mumps may slow initial antibody stimulation but does not prevent a strong protective response. The study also claims that adenoviruses, adeno-associated viruses, and lentivirus are used in gene therapy for cancer therapy, vaccines, and COVID-19 vaccines.

The most urgent invention is a COVID-19 vaccine, which teaches the immune system about the pathogen, specifically the coronavirus and its spike protein. The spike protein grabs cells and causes them to make billions of copies of the virus. Vaccines expose the body to something that looks like the virus, prompting the body to create antibodies to kill it. Vaccine creation usually involves injecting part of the virus's shape. This can be the whole virus, attenuated, or killed, or just a piece of the virus or the spike. A promising new method is the RNA vaccine, which uses RNA and DNA to provide instructions to make the spike shape. The Gates Foundation and partners are exploring these efforts. Creating a new vaccine typically takes at least 5 years, but there is optimism that a vaccine will be available in the next 18 months, produced in volume, and accessible to everyone, which is how the pandemic will end.

Robert F. Kennedy Jr.: Hi, it's Robert F. Kennedy Jr. here, your HHS secretary. At HHS, we have a division called the Biomedical Advanced Research and Development Authority, or BARDA. BARDA drives some of our most advanced scientific research. It funds developments of vaccines, drugs, diagnostics, and other tools to fight emerging diseases and national health threats. Over the past few weeks, BARDA reviewed 22 mRNA vaccine development investments and began canceling them. Let me explain why. Most of these shots are for flu or COVID, but as the pandemic showed us, mRNA vaccines don't perform well against viruses that infect the upper respiratory tract. Here's the problem: mRNA only codes for a small part of the viral proteins, usually a single antigen. One mutation and the vaccine becomes ineffective. This dynamic drives a phenomena called antigenic shift, meaning that the vaccine paradoxically encourages new mutations and can actually prolong pandemics as the virus constantly mutates to escape the protective effects of the vaccine. Millions of people, maybe even you or someone you know, caught the omicron variant despite being vaccinated. That's because a single mutation can make mRNA vaccines ineffective. The same risk applies to flu. After reviewing the science and consulting top experts at NIH and FDA, HHS has determined that mRNA technology poses more risk than benefits for these respiratory viruses. That's why after extensive review, BARDA has begun the process of terminating these 22 contracts totaling just under $500,000,000 To replace the troubled mRNA programs, we're prioritizing the development of the safer, broader vaccine strategies, like whole virus vaccines and novel platforms that don't collapse when viruses mutate. Let me be absolutely clear: HHS supports safe, effective vaccines for every American who wants them. That's why we're moving beyond the limitations of mRNA for respiratory viruses and investing in better solutions. Thank you. Produced by the U. S. Department of Health and Human Services.

- The mRNA vaccines, you know, from COVID don't work against upper respiratory infections. - There are two problems with them. - One is they target a single protein, which drives what what's called an antigenic shift. - If it drives the virus to mutate, and it actually can prolong the pandemic. - And we saw that during COVID, people took shots, mRNA shots for the original COVID variant and immediately, mutated into the Omicron virus to which the vaccine was ineffective, and that's what it does. - And the other issue is, that it the way that distributes in the body, the way that it migrates in the body, there's no control over and no predictability. - So it goes to every organ.

This video discusses the coronavirus and the ongoing research programs to develop vaccines against similar viruses that have previously crossed over from animals to humans. The question is raised whether these viruses can be modified or adapted to combat the current virus. This research is being conducted globally, including in China.

The panel discusses replication (replicon) vaccines and their potential dangers, focusing on how they differ from conventional messenger RNA (mRNA) vaccines and what new risks might emerge as this technology develops. Key points and concerns raised - Replicon vaccines concept and fundamental differences - Replicon vaccines use replication-capable genetic material, so the embedded genetic information not only makes antigen proteins but also multiplies inside the cell. They are described as having both constitutive function (the ability to make proteins) and, crucially, the capacity to replicate, which distinguishes them from traditional, non-replicating mRNA vaccines. - It is explained that replication introduces additional mutation and recombination opportunities, because the RNA genome is copied more than once, and the process can produce variants that differ from the original design. - Central dogma exceptions and viral biology - The speakers explain that while the central dogma (DNA → RNA → protein) generally governs biology, some viruses violate this, with RNA viruses that replicate via RNA-dependent replication and even some reverse-transcribing retroviruses that convert RNA to DNA and integrate into genomes. This context is used to frame why replicon vaccines could behave unpredictably. - Potential risks of replication and spread - A core concern is that the replicon approach might allow the vaccine genome to spread beyond the initial target cells, potentially reaching other cells and tissues, or even spreading to other people via exosomes or other means. Exosomes can transport DNA, RNA, and proteins between cells; thus, the replicon genome could in theory be disseminated. - The possibility of homologous or heterologous recombination between replicon genomes and wild-type viruses could yield new variants. The panel emphasizes the difficulty of controlling such recombination in a living system. - Specific material and design considerations - The use of viral components like spike protein genes in replicon vaccines raises concerns about how these proteins might mutate or recombine during replication, potentially altering antigen presentation or safety. - A concern is raised about the lack of repair mechanisms in RNA replication (as opposed to DNA replication), which could make error rates higher and lead to unpredictable changes. - The panel notes that current replicon vaccine designs (including those using alphavirus backbones) inherently carry high mutation and recombination risk, and that the replicating systems may encounter unpredictable evolutionary dynamics inside the human body. - Safety signals and clinical anecdotes - The speakers cite cases of adverse events temporally associated with vaccines, including vascular inflammation and thrombosis, stroke-like events, and myocarditis, to illustrate that immune responses to vaccines can be complex and occasionally severe. They emphasize that such observations do not establish causality, but argue they warrant careful scrutiny. - There are references to cases of acute vascular and neural complications following repeated vaccination, and to broader immune dysregulation phenomena, including IGG4-related disease and immune dysregulation syndromes that can involve multiple organs. - One example concerns a patient who developed sudden limb problems after the third dose, requiring surgery; another describes myocardial involvement after multiple doses and subsequent inflammatory sequelae. - DNA contamination and analytical findings - Kevin McKernan’s analysis of certain Japanese CoronaVac vaccines is cited: both DNA contamination and the presence of SV40 promoter elements were detected in some vaccine lots, with DNA amounts exceeding some regulatory benchmarks in at least one case. The concern is that DNA contamination, or the presence of promoter sequences, could influence integration or expression in unintended ways. - It is noted that vaccines using lipid nanoparticles can potentially deliver nucleic acids into cells; in the presence of exons or promoter sequences, there could be unintended cellular uptake and expression. - Implications for public health and policy - The panel underscores the need for caution, thorough investigation, and long-term observation of any replication-based vaccine platform before broad deployment. There is a call to evaluate risks, monitor long-term outcomes, and consider the possibility that replication-competent constructs could drive unforeseen evolutionary dynamics within hosts or communities. - There is contention about how information is communicated to the public, with particular emphasis on avoiding misinformation while ensuring that scientific uncertainties are transparently discussed. - Broader scientific context and forward-looking stance - The speakers discuss how the field’s approach to gene-based vaccines is evolving rapidly, and they stress that the compatibility of replicon systems with human biology is not yet fully understood. - They frame their discussion as not merely about current vaccines but about the trajectory of vaccine platforms: if replication-based or self-dispersing systems prove too risky or unpredictable, the prudent path might be to favor conventional, non-replicating strategies until safety, efficacy, and containment of unintended spread are more firmly established. Closing and takeaways - The session closes with emphasis on careful evaluation of replicon vaccines, awareness that viral genetics can behave differently in humans than in theory, and a call for continued discussion, independent verification, and transparent communication as the technology develops. - Throughout, speakers acknowledge the complexity of immune responses to vaccines, the potential for unexpected adverse events, and the importance of safeguarding public health while advancing vaccine science.

The most urgent invention is a COVID-19 vaccine, which teaches the immune system about the pathogen, specifically the coronavirus and its spike protein. The spike protein grabs cells and causes them to make billions of copies of the virus. Vaccines expose the body to something that looks like the virus, prompting the body to create antibodies to kill it. Vaccine creation usually involves injecting part of the virus's shape. This can be the whole virus (attenuated), a killed virus, or just a piece of the virus, like the spike. A promising new method is the RNA vaccine, which uses instructions to make the spike's shape. The Gates Foundation and partners are exploring these efforts. Creating a new vaccine typically takes at least 5 years, but there is optimism that a vaccine will be available in the next 18 months, produced in volume, and accessible worldwide, which is how the pandemic will end.

We're discussing the urgent need for a better flu vaccine that can protect against all types of influenza viruses. To tackle this challenge, we require passionate and talented individuals from diverse backgrounds to collaborate. By combining unconventional thinking, we can find faster solutions. Unlike measles, which remains consistent over time, influenza constantly changes due to mutations. This means that a new vaccine is needed each year to match the circulating virus. Occasionally, there are major changes in the virus caused by mutations or when it jumps species, resulting in a unique situation. Other viral infections like polio, smallpox, and measles do not exhibit this level of variability.